



LIFE SCIENCES DISCOVERY LIVES HERE

Ontario is taking life sciences to the next level, tackling some of the biggest challenges the world has ever seen. In 2022, the province released a comprehensive strategy to establish Ontario as a global biomanufacturing and life sciences hub leading the development, commercialization and early adoption of innovative health products and services.

Our diversified sector, collaborative spirit and deep talent pool are creating medical innovations that will improve health care delivery around the globe. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

ONTARIO'S LIFE SCIENCES SECTOR BY THE NUMBERS

OVER **50%**OF THE TOTAL CANADIAN LIFE SCIENCES ECONOMIC ACTIVITY

48 UNIVERSITIES AND COLLEGES PRODUCE MORE THAN 65K
STEM GRADUATES EACH YEAR

1,900 FIRMS
EMPLOYING MORE THAN
70,000 PEOPLE

49
INCUBATORS AND
ACCELERATORS ACROSS
THE PROVINCE

MORE THAN
\$11B
OF EXPORTED
LIFE SCIENCES GOODS

10 OF THE WORLD'S TOP
PHARMACEUTICAL COMPANIES
DO CLINICAL TRIALS HERE

ONTARIO'S EXPERTISE AND LEADERSHIP

The same innovative spirit that led to the discovery of insulin in Ontario decades ago is now leading to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal.

- Artificial intelligence
- Biotechnology
- Genomics

- Internet of things
- Medical devices
- Pharmaceuticals





The decision to invest in Ontario is a testament to the network of world-class universities, hospitals and research centers in the GTA and southern-Ontario, and the diverse scientific talent pool that exists in the region."

KIERSTEN COMBS PRESIDENT, ASTRAZENECA CANADA

ONTARIO'S VALUE PROPOSITIONS

1. TALENT

71% of working adults possess a post-secondary education





2. INNOVATION ECOSYSTEM

Business, academia and government work together to drive bold ideas to market

3. COMPETITIVE COSTS

Some of the lowest corporate taxes in North America Save up to 50% on after-tax R&D expenditures Source high quality products and services that are extremely cost-competitive





4. ACCESS TO GLOBAL MARKETS

A short distance to U.S. hubs Free trade agreements with 51 countries

5. DIVERSITY

People from 150 countries Over 200 languages spoken



WHO'S HERE

- 3M
- Abbott
- Apotex
- Baxter
- Blue Rock Therapeutics
- Cyclica
- Deep Genomics
- Fusion Pharmaceuticals
- GE Healthcare
- GSK
- Johnson & Johnson
- Novartis
- Octane
- Pfizer
- Roche
- Sanofi
- Siemens
- Strvker
- Teva
- VBI Vaccines



This information is accurate at the time of printing.

All figures are in Canadian dollars unless otherwise noted.